磁共振引导下前列腺穿刺活检:能否优化接受主动监测的前列腺癌患者定期活检的需求?一项重测信度预试验
回顾性分析7例患者共19个病灶的连续磁共振引导下前列腺穿刺活检(MRGB)结果,15个病灶(约79%)第二次活检病理一致,总体一致率78.9%、Kappa=0.55(p=0.002),首次活检前列腺癌阴性预测值87.5%;作者认为MRGB重复活检的信度可能优于经直肠超声引导活检,最终结论有待更大样本前瞻性分析。
要点
- MRGB重复活检总体一致率78.9%,Kappa=0.55提示中等一致(p=0.002)。
- 首次MRGB前列腺癌阴性预测值为87.5%。
- PI-RADS 1和4类病灶均为良性且病理一致,不一致病灶为PI-RADS 2、3、5类。
核心结论
- 磁共振引导下前列腺穿刺活检重复活检的信度可能优于经直肠超声引导活检,且提示较高阴性预测值,但最终结论有待更大样本前瞻性分析。
研究设计与样本
- 回顾性分析7例接受连续MRGB患者的19个病灶,5例接受2次连续MRGB、2例接受3次连续MRGB,多参数MRI和MRGB均使用3T MRI扫描仪,病理结果分为良性、可疑和恶性。
诊断标准与关键数值
- 19个病灶中15个(约79%)第二次活检病理一致、4个(21%)不一致,总体一致率78.9%、不一致率21.1%,Kappa=0.55(p=0.002)为中等一致,首次活检前列腺癌阴性预测值87.5%;19个病灶中10个接受第三次活检,其中9/10(90%)三次活检病理一致且均为良性。
临床应用与阅片要点
- 作者认为MRGB重复活检的信度可能优于经直肠超声引导活检,并提示较高阴性预测值;最终结论有待更大样本前瞻性分析。
局限性
- 本文为预试验(pilot study),样本为7例患者共19个病灶。
- 研究为回顾性分析。
- 最终结论有待更大样本前瞻性分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To evaluate the test-retest reliability of repeated in-bore MRI-guided prostate biopsy (MRGB).
METHODS: 19 lesions in 7 patients who had consecutive MRGBs were retrospectively analysed. Five patients had 2 consecutive MRGBs and two patients had 3 consecutive MRGBs. Both multiparametric MRI and MRGBs were performed using a 3T MRI scanner. Pathology results were categorized into benign, suspicious and malignant. Consistency between first and subsequent biopsy results were analysed as well as the negative predictive value (NPV) for prostate cancer.
RESULTS: 15 lesions (≈79%) had matching second biopsy and 4 (21%) had non-matching second biopsy. Lesions with both Prostate Imaging - Reporting and Data System(PIRADS) categories 1 and 4 were all benign and had matching pathology results. Lesions with non-matching results had PIRADS categories 2, 3 and 5. NPV for prostate cancer in first biopsy was 87.5%. Overall agreement was 78.9% and overall disagreement was 21.1%.κ = 0.55 denoting moderate agreement (p = 0.002). 10/19 lesions had a third biopsy session. 9/10 (90%) had matching pathology results across the three biopsy sessions and all matching lesions were benign.
CONCLUSION: In-bore MRI-guided prostate biopsy may have a better reliability for repeat biopsies compared to TRUS biopsy. Final conclusion awaits a prospective analysis on a larger cohort of patients. Advances in knowledge: This pilot study showed that repeated prostate in-bore MRI-guided prostate biopsy may have better reliability compared to TRUS biopsy with a suggested high NPV.
引用
- Elfatairy KK, Filson CP, Sanda MG, et al. In-bore MRI-guided biopsy: can it optimize the need for periodic biopsies in prostate cancer patients undergoing active surveillance? A pilot test-retest reliability study. Br J Radiol. 2018. PMID: 29308912. doi:10.1259/bjr.20170603
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。